Transparency data

Non-tech. summaries 2014: projects on human cancer

Projects granted during 2014 that have a primary purpose of translational and applied research: human cancer.

From:
Home Office
Published
25 April 2016

Documents

Non-technical summaries: projects granted in 2014, volume 11

PDF, 550 KB, 81 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2014 with a primary purpose of translational and applied research: human cancer.

The following projects were granted:

  • radiosensitisation of bladder tumours and normal tissues (bladder cancer, radiotherapy, radiosensitisation, normal tissue effects, orthotopic bladder model)

  • using mechanical stimuli to move therapies into tumours and vaccines across the skin (tumour, vaccine, mechanical, delivery, ultrasound)

  • virus based therapies in preclinical cancer models (adenovirus, cancer, oncolytic)

  • in-house service production monoclonal antibodies (monoclonal antibodies, infections, disease, diagnostics, vaccination)

  • engineering immunity to cancer (genetic modification, T-cells, cancer, therapy)

  • the isolation of novel antibody therapeutics for the treatment of human disease (antibody, cartilaginous fish, therapeutic drug)

  • molecular basis and theory of gynaecological cancer (ovarian cancer, gynaecological cancer, immunotherapy, chemotherapy)

  • developing selective, novel cancer therapeutics (cancer, drug discovery, therapeutics, preclinical)

  • targeting cancer stem cells and their micro environment (cancer stem cells, pancreatic cancer)

  • imaging in drug discovery (non-invasive, medical imaging, drug discovery)

  • the cause of resistance to treatment in human blood cancers (blood cancers, resistance, genome-damage)

  • experimental cancer diagnosis and therapy (cancer, tumour, diagnosis, therapy, models)

  • protecting stem cell and tissue function (stem cells, ageing, drug development, regeneration, mucositis)

  • nanomedicine based drug delivery (nanotechnology, drug development, brain diseases, biologics)

  • development of novel agents for cancer therapy (cancer, novel drugs)

  • development of personalised anti-cancer strategies (cancer, drugs, translation, biomarkers, metastasis)

  • micro environment signalling in cancer (cancer, micro environment, therapy)

  • novel multifunctional phage for guided systemic cancer gene therapy

  • evaluation of anti-cancer drugs (cancer, drugs)

  • epithelial-stromal interaction in cancer (cancer, stroma, epithelium, breast, lung)

  • biology of relapsed childhood leukaemia (leukaemia, drug-resistance, relapse, bone marrow micro environment)

  • immunisation of rodents (immunise antigens antibodies)

Published 25 April 2016

Related content